Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
United Sts Brent Oil Fd Lp Unit
BNO
5
United States Gasoline Fund Lp
UGA
US Stock MarketDetailed Quotes
Valneva (VALN)
- 6.890
- -0.170-2.41%
Close Sep 4 16:00 ET
- 6.890
- 0.0000.00%
Post 16:10 ET
653.33MMarket Cap-3.84P/E (TTM)
7.000High6.870Low22.87KVolume6.920Open7.060Prev Close158.08KTurnover0.03%Turnover RatioLossP/E (Static)94.82MShares12.23052wk High6.93P/B541.77MFloat Cap4.75052wk Low--Dividend TTM78.63MShs Float67.840Highest--Div Yield TTM1.84%Range %3.620Lowest6.913Avg Price1Lot Size
About Valneva Company
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
Company Profile
SymbolVALN
Company NameValneva
Issue Price26.41
ISINFR0004056851
Founded2015
CEOMr. Thomas Lingelbach
MarketNASDAQ
Employees674
Securities TypeDR
ADS Ratio1 : 2
Fiscal Year Ends12-31
AddressCampus Bio-Ouest,6, rue Alain Bombard
CitySaint-Herblain
ProvinceGE
CountryFrance
Zip Code44800
Phone33-2-28-07-37-10
Websitehttp://www.valneva.com
Company Executives
- Name
- Position
- Salary
- Thomas Lingelbach
- Director, President and Chief Executive Officer
- 939.56K
- Petra Pesendorfer
- Chief People Officer
- --
- Hanneke Schuitemaker
- Chief Scientific Officer
- --
- Dipal Patel
- Chief Commercial Officer
- 336.19K
- Vincent Dequenne
- Chief Operating Officer
- --
- Peter Buhler
- Chief Financial Officer
- 389.08K
- Dr. Juan Carlos Jaramillo, M.D.
- Chief Medical Officer
- 376.60K
- Anne-Marie Graffin
- Chairman of the Board
- 129.90K
- James R. Sulat
- Vice Chairman of the Board
- 111.15K
- Gerd Zettlmeissl
- Director
- 30.00K
- Dr. Kathrin Jansen, PhD
- Director
- 90.35K
- Daniele Guyot-Caparros
- Independent Director
- 73.30K
- James Connolly
- Independent Director
- 107.40K
- Kendra Wergin
- General Counsel and Corporate Secretary
- --
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On September 1, U.S. Eastern Time, the U.S. military launched a new round of strikes against Iran in response to recent attempts by the Isla
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm